View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
References<br />
Dynamic prediction of response to PEG-IFN 75<br />
1. van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Murad SD, de Man RA, Schalm SW,<br />
Janssen HL. Long-term follow-up of alpha-interferon treatment of patients with chronic<br />
hepatitis B. Hepatology 2004;39:804-10.<br />
2. Zoulim F, Perrillo R. Hepatitis B: refl ections on the current approach to antiviral therapy. J<br />
Hepatol 2008;48 Suppl 1:S2-19.<br />
3. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene<br />
ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and<br />
advanced liver disease. N Engl J Med 2004;351:1521-31.<br />
4. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So<br />
TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW. Pegylated<br />
interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic<br />
hepatitis B: a randomised trial. Lancet 2005;365:123-9.<br />
5. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW,<br />
Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N. Peginterferon Alfa-2a,<br />
lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med<br />
2005;352:2682-95.<br />
6. Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T,<br />
Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL. Sustained<br />
HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with<br />
peginterferon alpha-2b. Gastroenterology 2008;135:459-67.<br />
7. van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H, Heathcote J, Song<br />
BC, Janssen HL, de Man RA, Schalm SW. Durability of HBeAg seroconversion following<br />
antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum<br />
hepatitis B virus DNA and alanine aminotransferase. Gut 2003;52:420-4.<br />
8. van Zonneveld M, Flink HJ, Verhey E, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C,<br />
So TM, Gerken G, de Man RA, Hansen BE, Schalm SW, Janssen HL. The safety of pegylated<br />
interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose<br />
reduction and treatment discontinuation. Aliment Pharmacol Ther 2005;21:1163-71.<br />
9. Buster EH, Hansen BE, Lau KE, Piratvisuth T, McCloud PI, Button P, Steyerberg EW, Zeuzem<br />
S, Janssen HL. Prediction of response to peginterferon-alha in HBeAg positive chronic<br />
hepatitis B: a model based on 721 patients. Gastroenterology 2009;In press.<br />
10. Pas SD, Fries E, De Man RA, Osterhaus AD, Niesters HG. Development of a quantitative<br />
real-time detection assay for hepatitis B virus DNA and comparison with two commercial<br />
assays. J Clin Microbiol 2000;38:2897-901.<br />
11. Molenberghs G, Verbeke G. Models for discrete longitudinale data. Springer, 2005.<br />
12. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect<br />
of zidovudine on the survival of HIV-positive men. Epidemiology 2000;11:561-70.